Pilot gene completed 120 million a + round financing to accelerate the layout of digital PCR industry chain

EUROHEALTH news on July 19, recently, pilot gene announced the completion of 120 million yuan a + round of financing. This round of financing is led by shared investment, followed by Puxin capital, and the old shareholders continue to increase their weight. This round of financing will be used to accelerate the layout of digital PCR circuit, including the development of multiple sets of innovative equipment platforms, the research and development of a variety of molecular diagnostic reagents, clinical trials and registration, promote its application in life science and medicine, expand the sales team and market promotion, etc., so as to lay a solid foundation for the deep cultivation of pilot gene in the field of molecular diagnosis. Pilot gene is committed to the R & D, production and sales of products in the upper and middle reaches of the digital PCR industry chain. The products cover equipment, chips and in vitro diagnostic reagents related to digital PCR technology, providing users with the best overall solution. Since its establishment in 2014, it has launched a series of products registration and listing continuously and efficiently. In 2018, China's first three color fluorescent channel chip digital PCR system (c2400) with independent intellectual property rights was approved to go on the market. In 2019, the new five color fluorescent channel droplet digital PCR system (d3200) will be launched. In 2020, the upgraded seven color fluorescent biochip reader CS7 of d3200 will continue to be launched, and the fully automatic digital PCR system construction system (AP10) will be promoted The full-automatic droplet digital PCR system (AD16) is on the market. By 2021, the complete set of CS Series biochip reader has been approved (three to seven color fluorescence channel Series), leading gene to continuously improve the digital PCR product line.